Showing results (1-10 of 71) with videos related to
Sort By:
Pageof 8
Annual Review of Pharmacology and Toxicology|November 1, 2011
Factors controlling nanoparticle pharmacokinetics: an integrated analysis and perspectiveS M Moghimi, A C Hunter, T L AndresenMolecular Immunology|March 17, 2009
Complement-mediated tumour growth: implications for cancer nanotechnology and nanomedicinesS M Moghimi, T L AndresenJournal of Innate Immunity|June 23, 2012
Particulate systems for targeting of macrophages: basic and therapeutic conceptsS M Moghimi, L Parhamifar, D Ahmadvand, et al.Pharmaceutical Research|May 5, 2001
Recognition by macrophages and liver cells of opsonized phospholipid vesicles and phospholipid headgroupsS M Moghimi, A C HunterTrends in Biotechnology|September 22, 2000
Poloxamers and poloxamines in nanoparticle engineering and experimental medicineS M Moghimi, A C HunterCritical Reviews in Therapeutic Drug Carrier Systems|January 16, 2002
Capture of stealth nanoparticles by the body's defencesS M Moghimi, A C HunterJournal of Controlled Release : Official Journal of the Controlled Release Society|April 15, 2010
Complement activation cascade triggered by PEG-PL engineered nanomedicines and carbon nanotubes: the challenges aheadS M Moghimi, A J Andersen, S H Hashemi, et al.FEBS Letters|December 17, 2002
PEGylation of microspheres generates a heterogeneous population of particles with differential surface characteristics and biological performanceJ K Gbadamosi, A C Hunter, S M MoghimiFEBS Letters|July 16, 2003
Real-time evidence of surface modification at polystyrene lattices by poloxamine 908 in the presence of serum: in vivo conversion of macrophage-prone nanoparticles to stealth entities by poloxamine 908S M Moghimi, K D Pavey, A C HunterPharmacological Reviews|May 18, 2001
Long-circulating and target-specific nanoparticles: theory to practiceS M Moghimi, A C Hunter, J C MurrayPageof 8